Intersect ENT Stock News

Intersect ENT (XENT) first-quarter revenues improved year over year on increased PROPEL and SINUVA sales.

Intersect ENT, Inc. (XENT) CEO Tom West on Q1 2021 Results - Earnings Call Transcript

Intersect ENT (XENT) delivered earnings and revenue surprises of -21.43% and 4.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

PROPEL and SINUVA are expected to have contributed to Intersect ENT's (XENT) first-quarter revenues.

Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 5.56% year over year to ($0.51), which missed the estimate of

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate at Upcoming Investor Conferences

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Changes to its Board of Directors

Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.

Intersect ENT (XENT) is worried about the first-quarter performance as well on the significant surge in COVID-19 case rates.

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Intersect ENT's (XENT) sequentially rebound is strong on continued recovery in PROPEL, growth in SINUVA and initial sales of the company???s newly acquired Fiagon products.

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference

Intersect ENT, Inc. (XENT) CEO Tom West on Q4 2020 Results - Earnings Call Transcript

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Fourth Quarter 2020 Financial Results